In this episode, John Stanford breaks down the surge in U.S. biomanufacturing investments, including Virginia’s new $500B hub, and what it means for the nation’s workforce. He contrasts this expansion with the recent closure of Arena BioWorks, raising questions about the balance between onshoring and sustaining innovation. The discussion also dives into major rumors of a potential Medicare-GLP-1 deal with Eli Lilly and Novo Nordisk and explores the possible implications of new CMS demonstration projects that could impact Part B manufacturers. Finally, John reflects on the growing pressure of tax and pricing policies that could reshape the biotech landscape. Do you think the U.S. is striking the right balance between manufacturing and innovation? How might Medicare coverage of GLP-1 drugs change the healthcare system? What policy signals should Congress send to protect early-stage biotech?If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: https://x.com/MakingMedPodhttps://www.instagram.com/makingmedicinepod/https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true0:00 Disclaimer and introduction0:23 Welcome to the Making Medicine Podcast0:57 FDA leadership shakeup and industry uncertainty2:06 Arena BioWorks closure and policy contrasts2:32 FDA predictability and regulatory challenges3:28 Medicare and GLP-1 coverage discussion4:08 New FDA guidance on biosimilars and gene editing5:00 FDA moves to reduce biosimilar development costs5:49 Gene editing progress and regulatory flexibility6:53 Impact of pricing and revenue policies on innovation7:48 Arena BioWorks shutdown and biotech investment climate10:40 Virginia’s new manufacturing hub and workforce initiative13:14 White House drug pricing rumors and CMMI demonstration projects17:39 Closing thoughts and call for engagement DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.

Ver todos los episodios